Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Wee…

Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be ...

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegu…

Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be ...